<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01127295</url>
  </required_header>
  <id_info>
    <org_study_id>09 SEIN 09</org_study_id>
    <nct_id>NCT01127295</nct_id>
  </id_info>
  <brief_title>Pharmacology of Adjuvant Hormonotherapy in Breast Cancer</brief_title>
  <acronym>PHACS</acronym>
  <official_title>Breast Cancer Adjuvant Hormonotherapy : Tamoxifen and the Anti-aromatases Pharmacokinetics, Correlation With the Pharmacogenetic Characteristics PHACS Protocol : Pharmacology of Adjuvant Hormonotherapy in Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a biomedical study of interventional type, multicenter, inter-regional.

      Patients with hormono-depending breast cancer, for which an indication of adjuvant
      hormonotherapy treatment (according to the current treatments) was retained, will be enrolled
      in this study. The main objective is to estimate the correlations between pharmacokinetic and
      pharmacogenetic parameters of adjuvant hormonal breast cancer treatment, during the first 3
      years.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 17, 2010</start_date>
  <completion_date type="Actual">December 1, 2017</completion_date>
  <primary_completion_date type="Actual">December 1, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between pharmacokinetic and pharmacogenetic parameters</measure>
    <time_frame>9 years</time_frame>
    <description>To estimate the correlations between pharmacokinetic and pharmacogenetic parameters of hormonal adjuvant breast cancer treatment during the first 3 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To estimate the relation between plasmatic concentrations, pharmacogenetic characteristic and adverse effects.</measure>
    <time_frame>9 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate the relation between the genetic polymorphisms and premature relapses in the first 3 years of treatment</measure>
    <time_frame>9 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate the link between plasmatic concentrations and the premature relapse (in the first 3 years)</measure>
    <time_frame>9 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate the declared therapeutic observance to the real exposure at the treatment measured by plasmatic concentrations.</measure>
    <time_frame>9 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>appearance auto-antibody and correlate to the clinical data</measure>
    <time_frame>9 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2000</enrollment>
  <condition>Hormono-depending Adjuvant Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Tamoxifen, Anastrozole, letrozole, Exemestane</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Current hormonotherapy treatment in hormono dependent breast cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen, Letrozole, Anastrozole or Exemestane</intervention_name>
    <description>Tamoxifen 20 mg/day during 5 years Létrozole 2.5 mg/day during 5 years Anastrozole 1 mg/day during 5 years Exémestane 25 mg/day during 5 years</description>
    <arm_group_label>Tamoxifen, Anastrozole, letrozole, Exemestane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient of more than 18 years old (menopaused or not)

          2. Invasive breast cancer non-metastatic locally controlled by surgery with or without
             radiotherapy. Previous treatment with chemotherapy is allowed including trastuzumab

          3. Cancer hormone-expressing ER and / or PR (&gt; 10% tumor cells in Technical HIC)

          4. Having a staging exploring bone, liver, lung and showing no abnormality secondary (for
             sub-centimeter tumors, the staging is not necessary)

          5. WHO &lt;2

          6. Before the initiation of adjuvant hormonal therapy (tamoxifen, anastrozole, letrozole
             or exemestane) and whatever the approach chosen by the investigator (5 years of
             tamoxifen, 5 years of anti-aromatase or sequential patterns)

          7. signed Consent collected before any specific procedure in the study

          8. Patient member in a national insurance scheme.

        Exclusion Criteria:

          1. Patient previously treated for breast cancer receiving hormonal therapy with
             tamoxifen, anastrozole, letrozole or exemestane regardless of the scheme

          2. Metastatic Breast cancer

          3. History of another cancer diagnosed within 5 years before or uncontrolled except
             carcinoma in situ of cervix carcinoma, nonmelanoma skin, breast cancer (in this case,
             treatment with hormone therapy should be stopped for at least 6 months)

          4. Any other medical or psychiatric condition or laboratory abnormality severe acute or
             chronic making the inclusion of the patient in the study inappropriate in the opinion
             of the investigator

          5. Patient unable to follow procedures, visits, examinations described in the study

          6. Pregnant women or nursing mothers can not participate in the study

          7. Women of childbearing age must use effective contraception at study entry and up to at
             least three months after the end of treatment

          8. Patient under legal guardianship
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henri ROCHE, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Claudius Regaud</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinique Calabet</name>
      <address>
        <city>Agen</city>
        <zip>47000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Claude Bernard</name>
      <address>
        <city>Albi</city>
        <zip>81030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier d'Auch</name>
      <address>
        <city>Auch</city>
        <zip>32008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Tivoli</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique Bordeaux Nord</name>
      <address>
        <city>Bordeaux</city>
        <zip>33077</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Brive</name>
      <address>
        <city>Brive La Gaillarde</city>
        <zip>19312</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Cahors</name>
      <address>
        <city>Cahors</city>
        <zip>46005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal de Castres-Mazamet</name>
      <address>
        <city>Castres</city>
        <zip>81108</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Dupuytren CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Mont de Marsan</name>
      <address>
        <city>Mont de Marsan</city>
        <zip>40024</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Montauban</name>
      <address>
        <city>Montauban</city>
        <zip>82013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Caremeau CHU Nîmes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Pau</name>
      <address>
        <city>Pau</city>
        <zip>64000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Catalan d'Oncologie</name>
      <address>
        <city>Perpignan</city>
        <zip>66000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Rodez</name>
      <address>
        <city>Rodez</city>
        <zip>12000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique de l'Ormeau</name>
      <address>
        <city>Tarbes</city>
        <zip>65000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur - Département d'Oncologie Médicale</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur - Département de Radiothérapie</name>
      <address>
        <city>Toulouse</city>
        <zip>31300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Saint-Jean du Languedoc</name>
      <address>
        <city>Toulouse</city>
        <zip>31400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2010</study_first_submitted>
  <study_first_submitted_qc>May 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2010</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacogenetic</keyword>
  <keyword>tamoxifen</keyword>
  <keyword>anti-aromatases</keyword>
  <keyword>breast cancer</keyword>
  <keyword>pharmacodynamy</keyword>
  <keyword>Observance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Exemestane</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

